)
Visual
test
C4 Therapeutics
C4 Therapeutics (CCCC) investor relations material
C4 Therapeutics Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary3 Dec, 2025
Clinical program updates
Two active clinical programs: cemsidomide (IKZF1/3 degrader) and CFT8919 (EGFR L858R degrader) are progressing, with cemsidomide moving to the next phase early next year and CFT8919 in a phase one study in China.
Cemsidomide phase one showed a 36% ORR overall, with 40% and 53% ORR at the two highest doses; two complete responses observed at 100 mcg.
Safety profile for cemsidomide is favorable, with no discontinuations due to safety and only 6% dose reductions; most adverse events were not drug-related.
100% of patients were triple-class exposed, and 75% had prior CAR T or T-cell engager therapy; response rates were consistent across these subgroups.
Cemsidomide's efficacy and safety profile compare favorably to mezigdomide, with a more refractory patient population and fewer neutropenic complications.
Regulatory and development plans
No further phase one updates planned for cemsidomide; focus is on advancing to phase two, with an FDA meeting on dose alignment scheduled for later this month.
A prior Type C meeting with the FDA provided feedback shaping current development plans.
The upcoming global 4L+ study will enroll triple-class refractory patients, with a target ORR of around 40% to demonstrate significant improvement over the 20% background rate.
Confidence in single-arm study approval is based on precedent, but regulatory risk remains due to evolving standards and agency personnel.
Commercial and financial outlook
Pricing for cemsidomide is expected to be competitive with current market analogs, but specifics are not disclosed.
Duration of response in late-line settings is currently 9.3 months, exceeding the typical six-month benchmark.
Cash runway extends through the end of 2028, not including up to $40 million in potential milestone payments from partners over 2026–2027.
Key data readouts from the phase two MOMENTUM study are expected by late 2027 (investigator assessment) and later in 2028 (central assessment).
Cemsidomide's competitive edge vs. Mezigdomide?
Confidence in single-arm cemsidomide approval?
CFT8919 development plan post-Q1 2026 decision?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- DANSKE
Record core income and strong credit quality drove DKK 23.0bn net profit; 2026 outlook positive. - DANSKERecord core income, strong credit quality, and 100% profit distribution define 2025 results.
- 7211
Net sales and profits fell year-over-year, but recent earnings show gradual recovery. - 524742
Strong revenue and profit growth with robust margins and expanding global presence in Q3 FY26. - ANTHEM
Q3 FY26 saw robust revenue, profit growth, and capital increase post-IPO and ESOP allotments. - AFRY
Margin and utilization gains in Q4 offset lower sales and profit amid market challenges. - 8111
Sales and operating profit rose, but net profit fell on lower affiliate gains; outlook steady. - 7731
Large impairment in Digital Manufacturing and weak sales led to sharp losses and a weaker outlook. - 6370
Profits and sales rose, led by General Industry, with robust capital actions and a positive outlook. - 9312
Profits and dividends rose on strong domestic logistics, with improved financial stability.
Next C4 Therapeutics earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
C4 Therapeutics
Next C4 Therapeutics earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
C4 Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop novel therapies. The company is active in the development of small-molecule medicines designed to selectively target and degrade disease-causing proteins. C4 Therapeutics is leveraging its proprietary technology platforms to advance a pipeline of drug candidates aimed at treating a range of diseases, such as cancer, neurodegenerative conditions, infectious diseases, and autoimmune disorders. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq under the symbol CCCC.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage